Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inhye E Ahn

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Blood|March 29, 2019
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLLInhye E Ahn, Neil Basumallik, Xin Tian, et al.
Kidney International Reports|September 18, 2024
Masked Arginine Vasopressin Deficiency in a Kidney Transplant Recipient With Posttransplant Lymphoproliferative DisorderAnnie Liu, Lakshmi Nayak, Waihay J Wong, et al.
Clinical Rheumatology|October 8, 2009
Radiologic observation: repair of focal bone erosions after humanized antitumor necrosis factor antibody adalimumab therapy in a patient with rheumatoid arthritisInhye E Ahn, Ji Hyeon Ju, Sung-Hwan Park, et al.
Blood|August 10, 2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinibInhye E Ahn, Theresa Jerussi, Mohammed Farooqui, et al.
Clinical Rheumatology|November 10, 2009
The silent progression of metastatic malignancy during the treatment with soluble tumor necrosis factor receptorInhye E Ahn, Ji Hyeon Ju, Kwi Young Kang, et al.
The Laryngoscope|July 28, 2010
Cost analysis of asymmetric sensorineural hearing loss investigationsYuShan L Wilson, Michele M Gandolfi, Inhye E Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2021
Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with IbrutinibMaria Joao Baptista, Sivasubramanian Baskar, Erika M Gaglione, et al.
Leukemia & Lymphoma|July 7, 2018
Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapyAlankrita Taneja, Jade Jones, Stefania Pittaluga, et al.
British Journal of Haematology|December 5, 2021
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trialsJohn N Allan, Tait Shanafelt, Adrian Wiestner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2021
Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with IbrutinibChristian Brieghel, Kathrine Aarup, Mathias H Torp, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Blood|March 29, 2019
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLLInhye E Ahn, Neil Basumallik, Xin Tian, et al.
Kidney International Reports|September 18, 2024
Masked Arginine Vasopressin Deficiency in a Kidney Transplant Recipient With Posttransplant Lymphoproliferative DisorderAnnie Liu, Lakshmi Nayak, Waihay J Wong, et al.
Clinical Rheumatology|October 8, 2009
Radiologic observation: repair of focal bone erosions after humanized antitumor necrosis factor antibody adalimumab therapy in a patient with rheumatoid arthritisInhye E Ahn, Ji Hyeon Ju, Sung-Hwan Park, et al.
Blood|August 10, 2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinibInhye E Ahn, Theresa Jerussi, Mohammed Farooqui, et al.
Clinical Rheumatology|November 10, 2009
The silent progression of metastatic malignancy during the treatment with soluble tumor necrosis factor receptorInhye E Ahn, Ji Hyeon Ju, Kwi Young Kang, et al.
The Laryngoscope|July 28, 2010
Cost analysis of asymmetric sensorineural hearing loss investigationsYuShan L Wilson, Michele M Gandolfi, Inhye E Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2021
Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with IbrutinibMaria Joao Baptista, Sivasubramanian Baskar, Erika M Gaglione, et al.
Leukemia & Lymphoma|July 7, 2018
Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapyAlankrita Taneja, Jade Jones, Stefania Pittaluga, et al.
British Journal of Haematology|December 5, 2021
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trialsJohn N Allan, Tait Shanafelt, Adrian Wiestner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2021
Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with IbrutinibChristian Brieghel, Kathrine Aarup, Mathias H Torp, et al.
Pageof 6